INFLARX NV · Data as of 2026-09-08
next year
In addition, the Company has announced its goal of establishing rapid proof of concept for izicopan across a broader range of complement-mediated life-threatening kidney diseases by conducting open-label studies that are expected to begin generating clinical data next year in certain indications.Source filing
through 2029
InflaRx estimates it will have sufficient funds to execute currently planned development programs through meaningful milestones, including proof-of-concept data readouts in aHUS, IgAN and C3G, the Phase 2 data readout in AAV, as well as ongoing operations, through 2029.Source filing
summer 2026
Capital Markets Day highlighting the promise and potential of izicopan in AAV and broader renal disorders now planned for summer 2026Source filing